Duke University School of Medicine, Durham, North Carolina 27710, USA.
Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.
Annu Rev Med. 2022 Jan 27;73:279-292. doi: 10.1146/annurev-med-042420-102102. Epub 2021 Oct 19.
Faced with unique immunobiology and marked heterogeneity, treatment strategies for glioblastoma require therapeutic approaches that diverge from conventional oncological strategies. The selection and prioritization of targeted and immunotherapeutic strategies will need to carefully consider these features and companion biomarkers developed alongside treatment strategies to identify the appropriate patient populations. Novel clinical trial strategies that interrogate the tumor microenvironment for drug penetration and target engagement will inform go/no-go later-stage clinical studies. Innovative trial designs and analyses are needed to move effective agents toward regulatory approvals more rapidly.
面对独特的免疫生物学和显著的异质性，胶质母细胞瘤的治疗策略需要采用与传统肿瘤学策略不同的治疗方法。选择和优先考虑靶向和免疫治疗策略需要仔细考虑这些特征以及伴随治疗策略开发的伴随生物标志物，以确定合适的患者人群。探索肿瘤微环境中的药物渗透和靶点结合的新型临床试验策略将为后期临床试验的去留提供信息。需要创新的试验设计和分析方法，以使有效的药物更快获得监管部门的批准。
